Youfei Guan Selected Research

PPAR delta

8/2008	Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice.
2/2008	Suppression of pro-inflammatory adhesion molecules by PPAR-delta in human vascular endothelial cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Youfei Guan Research Topics

Disease

14	Inflammation (Inflammations) 10/2020 - 04/2002
12	Type 2 Diabetes Mellitus (MODY) 09/2020 - 04/2002
10	Insulin Resistance 12/2013 - 04/2002
9	Fibrosis (Cirrhosis) 11/2021 - 08/2007
8	Obesity 01/2018 - 11/2004
7	Non-alcoholic Fatty Liver Disease 01/2019 - 08/2008
7	Diabetic Nephropathies (Diabetic Nephropathy) 07/2015 - 04/2002
6	Hypertension (High Blood Pressure) 03/2018 - 11/2004
6	Hyperglycemia 01/2017 - 04/2002
6	Fatty Liver 01/2017 - 08/2013
5	Albuminuria 10/2010 - 11/2004
4	Proteinuria 03/2018 - 08/2006
4	Vascular Calcification 01/2016 - 05/2011
4	Kidney Diseases (Kidney Disease) 01/2013 - 05/2008
4	Atherosclerosis 01/2012 - 11/2004
3	Acute Kidney Injury (Acute Renal Failure) 02/2022 - 01/2021
3	Ischemia 12/2021 - 01/2013
3	Chronic Renal Insufficiency 11/2021 - 01/2009
3	Wounds and Injuries (Trauma) 01/2020 - 06/2011
3	Asthma (Bronchial Asthma) 01/2020 - 02/2016
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2018 - 11/2005
3	Chronic Kidney Failure (Chronic Renal Failure) 01/2016 - 05/2011
3	Glucose Intolerance 11/2014 - 11/2004
3	Glomerulonephritis 08/2006 - 08/2002
2	Hypertrophy 10/2020 - 01/2015
2	Liver Diseases (Liver Disease) 01/2019 - 08/2008
2	Neointima 01/2018 - 08/2011
2	Autoimmune Diseases (Autoimmune Disease) 06/2015 - 01/2012
2	Dyslipidemias (Dyslipidemia) 11/2014 - 11/2004
2	Hypertriglyceridemia 08/2014 - 09/2008
2	Reperfusion Injury 05/2014 - 01/2013
2	Uremia 06/2013 - 05/2011
2	Tuberous Sclerosis (Bourneville's Disease) 03/2013 - 01/2010
1	Pneumococcal Infections 01/2022
1	Ureteral Obstruction 01/2021
1	Cardiomyopathies (Cardiomyopathy) 10/2020
1	Vascular Diseases (Vascular Disease) 10/2020
1	Liver Neoplasms (Liver Cancer) 01/2019

Drug/Important Bio-Agent (IBA)

11	LipidsIBA 01/2019 - 04/2002
10	Glucose (Dextrose)FDA LinkGeneric 01/2015 - 04/2002
8	Dinoprostone (PGE2)FDA Link 10/2020 - 08/2006
7	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2012 - 11/2004
7	LigandsIBA 01/2012 - 04/2002
7	PPAR gammaIBA 01/2012 - 04/2002
6	Proteins (Proteins, Gene)FDA Link 08/2014 - 07/2012
6	Insulin (Novolin)FDA Link 02/2012 - 05/2005
5	CytokinesIBA 11/2021 - 12/2009
5	Triglycerides (Triacylglycerol)IBA 12/2014 - 09/2008
5	Transcription Factors (Transcription Factor)IBA 01/2012 - 04/2002
4	ProstaglandinsIBA 01/2020 - 08/2006
4	PPAR alphaIBA 05/2008 - 11/2004
3	Pregnane X ReceptorIBA 02/2022 - 01/2021
3	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2020 - 01/2008
3	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 03/2018 - 06/2006
3	Small Interfering RNA (siRNA)IBA 01/2018 - 01/2013
3	AdipokinesIBA 01/2018 - 04/2013
3	Fatty Acids (Saturated Fatty Acids)IBA 01/2017 - 09/2008
3	CalciumIBA 01/2016 - 05/2011
3	Hypoglycemic Agents (Hypoglycemics)IBA 03/2014 - 11/2004
3	ThiazolidinedionesIBA 01/2009 - 04/2002
3	PPAR-gamma AgonistsIBA 12/2005 - 11/2004
2	Cisplatin (Platino)FDA LinkGeneric 02/2022 - 01/2021
2	CollagenIBA 01/2021 - 08/2007
2	Biomarkers (Surrogate Marker)IBA 09/2020 - 01/2019
2	Immunoglobulin E (IgE)IBA 01/2020 - 02/2016
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019 - 05/2011
2	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2019 - 11/2005
2	Angiotensin IIIBA 01/2019 - 03/2018
2	Pharmaceutical PreparationsIBA 01/2017 - 06/2011
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2016 - 10/2010
2	Prostaglandin-E SynthasesIBA 01/2016 - 04/2014
2	Adenine FDA LinkGeneric 01/2016 - 05/2011
2	Interleukin-17 (Interleukin 17)IBA 06/2015 - 01/2012
2	Sterol Regulatory Element Binding Protein 1IBA 12/2014 - 08/2014
2	Adenosine Triphosphate (ATP)IBA 03/2014 - 03/2014
2	SodiumIBA 06/2013 - 06/2006
2	Phosphates (Orthophosphate)IBA 06/2013 - 05/2011
2	Mn(III) 5,10,15,20- tetrakis(N- methylpyridinium- 2- yl)porphyrinIBA 06/2013 - 05/2011
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2013 - 09/2009
2	NF-kappa B (NF-kB)IBA 07/2012 - 12/2009
2	Fenofibrate (CiL)FDA LinkGeneric 01/2012 - 06/2011
2	Cytochrome P450 Family 4IBA 05/2011 - 06/2006
2	Protein Isoforms (Isoforms)IBA 01/2009 - 11/2004
2	PPAR deltaIBA 08/2008 - 02/2008
2	2,4-thiazolidinedione (thiazolidinedione)IBA 05/2008 - 04/2002
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 09/2007 - 08/2006
1	Immunoglobulin M (IgM)IBA 01/2022
1	Folic Acid (Vitamin M)FDA LinkGeneric 11/2021
1	LuciferasesIBA 01/2021
1	Fibronectins (Fibronectin)IBA 01/2021
1	Isoproterenol (Isoprenaline)FDA LinkGeneric 10/2020
1	Adrenergic Receptors (Adrenergic Receptor)IBA 10/2020
1	trichrome stainIBA 10/2020
1	MicroRNAs (MicroRNA)IBA 09/2020
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2020
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 01/2019

Therapy/Procedure

2	Therapeutics 09/2014 - 12/2005
2	Glycemic Control 05/2010 - 08/2007
1	Immunomodulation 11/2021
1	Injections 10/2020